171 related articles for article (PubMed ID: 12127662)
1. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
2. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
Grigoriadis N
Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
[No Abstract] [Full Text] [Related]
3. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
Goodin DS
Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
[TBL] [Abstract][Full Text] [Related]
4. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
Hartung HP
Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200
[TBL] [Abstract][Full Text] [Related]
5. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
6. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
7. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino R
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
[No Abstract] [Full Text] [Related]
8. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E
Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
[TBL] [Abstract][Full Text] [Related]
9. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
Hohlfeld R
Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
[No Abstract] [Full Text] [Related]
10. Treat early, but treat hard: Interferon-beta dose makes a difference.
Mikol DD
J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
[No Abstract] [Full Text] [Related]
11. [Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations].
Mäurer M; Gold R; Toyka KV; Rieckmann P
Nervenarzt; 2001 Feb; 72(2):108-16. PubMed ID: 11256144
[TBL] [Abstract][Full Text] [Related]
12. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
Blumhardt LD
Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
[TBL] [Abstract][Full Text] [Related]
13. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
14. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
15. Interferon beta-1a in relapsing-remitting multiple sclerosis.
Blumhardt L
Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
[TBL] [Abstract][Full Text] [Related]
16. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
17. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
18. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
19. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]